ARMP (ARMP) Stock Analysis
Verdict: AVOID
Critical cash runway of ~4 months and $288M debt outweigh FDA Breakthrough status, creating severe dilution risk.
Investment score: 24/100
The AI model assesses Armata Pharmaceuticals as an AVOID due to severe cash burn, a balance sheet featuring $288.02M in total debt against negative equity, and an estimated cash runway of under 4 months. Although FDA Breakthrough Therapy designation for AP-SA02 provides clinical validation, upcoming capital raises pose extreme dilution risks for existing shareholders.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| CNTN | -1.35 | 1.01 | 109.56 | -1.44 | — | -65.59 |
| MNOV | -15.03 | 4.31 | 174.59 | -12.34 | — | -11.68 |
| RNA | -2.48 | 0.76 | 6.96 | -0.97 | — | -3.97 |
| HUMA | -1.15 | 4.38 | 46.27 | -1.06 | — | -45.61 |
| SPRB | -1.33 | 1.58 | 0.00 | -1.26 | — | 0.00 |